Related Experiment Video
Updated: Jun 17, 2026
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Safety of mycophenolate mofetil monotherapy in patients after liver transplantation
Carsten Kamphues1, Roberta Bova, Christoph Röcken
1Department of General, Visceral and Transplantation Surgery, Universitätsklinikum Charité, Campus Virchow-Klinikum, Humboldt-Universität, Berlin, Germany. carsten.kamphues@charite.de
Background:
Due to the nephrotoxicity of calcineurin inhibitors (CNIs) mycophenolate mofetil (MMF) has become a promising immunosuppressive alternative in recent years. In several studies an improvement of renal function could be reached by introduction of MMF and withdrawal of CNIs but there is few known about the long-term effects of MMF on liver-, kidney- and bone marrow function.
Material And Methods:
We therefore retrospectively reviewed 123 adult liver transplant patients who were successfully converted to MMF monotherapy without any acute rejection within the first three months of MMF monotherapy.
Results:
Serum levels of liver enzymes as well as white blood cells did not show any significant difference between the time of conversion and after 1 year but a significant reduction in serum creatinine could be evaluated (1.47 mg/dl vs. 1.54 mg/dl). In 59 patients liver biopsies were performed before and after introduction of MMF monotherapy. None displayed signs of chronic rejection during MMF monotherapy but there was a slight increase of the fat content of the liver (16.1% vs. 9.8%).
Conclusions:
In conclusion after successful conversion to MMF monotherapy this regime is safe and effective and the long-term effects of MMF monotherapy on the liver tissue are minor. Furthermore renal function can be improved without considerable effects on the bone marrow.
Insights
Mycophenolate mofetil (MMF) monotherapy is a safe and effective immunosuppressant after liver transplant. It improves kidney function with minimal long-term impact on liver and bone marrow health.
Area of Science:
- Transplantation Immunology
- Hepatology
- Nephrology
Background:
- Calcineurin inhibitors (CNIs) exhibit nephrotoxicity, leading to increased use of mycophenolate mofetil (MMF) as an alternative immunosuppressant.
- While MMF shows promise in improving renal function post-transplant, long-term effects on liver, kidney, and bone marrow require further investigation.
Purpose of the Study:
- To evaluate the long-term safety and efficacy of MMF monotherapy in liver transplant recipients.
- To assess the impact of MMF monotherapy on liver, kidney, and bone marrow function.
Main Methods:
- Retrospective review of 123 adult liver transplant patients converted to MMF monotherapy.
- Analysis of liver enzymes, white blood cell counts, serum creatinine, and liver biopsies before and after MMF introduction.
Main Results:
- No significant changes in liver enzymes or white blood cells were observed after one year of MMF monotherapy.
- A significant reduction in serum creatinine indicated improved renal function.
- Liver biopsies showed a slight increase in fat content but no signs of chronic rejection.
Conclusions:
- MMF monotherapy is a safe and effective immunosuppressive strategy post-liver transplant.
- Long-term MMF use has minor effects on liver tissue and can improve renal function without significant bone marrow impact.
Related Concept Videos
01:26Kidney Transplant II: Surgical Procedure
01:16Kidney Transplant III: Nursing Management
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
01:24Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
01:27Cryptococcal Meningitis
01:28Kidney Transplant I: Introduction